Other languages AngioDynamics, Inc.

Equities

ANGO

US03475V1017

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-03 pm EDT			5-day change	1st Jan Change
6.27 ^USD	+3.12%		+7.92%	-20.03%

Apr. 08	North American Morning Briefing : Inflation Data, -2-	DJ
Apr. 05	Oppenheimer Upgrades AngioDynamics to Outperform From Perform, $12 Price Target	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AngioDynamics Shares Jump After Fiscal Q3 Results, FDA Clearance For Device	Apr. 04
AngioDynamics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024	Apr. 04
AngioDynamics, Inc. Provides Sales Guidance for the Fiscal Year 2024	Apr. 04
AngioDynamics, Inc. Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE	Apr. 04
AngioDynamics Settles Patent Dispute with Becton, Dickinson Affiliate	Apr. 01
AngioDynamics Sells Two Product Lines to Spectrum Vascular for up to $45 Million Cash; Shares Up in Pre-Bell Trading	Feb. 16
Spectrum Vascular acquired PICC and Midline Product Portfolios from AngioDynamics, Inc. for $45 million.	Feb. 14
Angiodynamics, Inc. Announces Board Changes	Feb. 13
AngioDynamics Receives FDA Clearance for Auryon XL Radial Access Catheter	Jan. 23
Angiodynamics Announces FDA 510(K) Clearance of Auryon Xl Radial Access Catheter to Treat Peripheral Arterial Disease	Jan. 23
AngioDynamics, Inc. Announces Dennis Meteny to Retire as A Member of the Board of Directors, Member of the Compensation Committee and Chair of the Audit Committee, Effective January 31, 2024	Jan. 22
Sector Update: Health Care Stocks Retreat Late Afternoon	Jan. 05
AngioDynamics Shares Fall After Q2 Swing to Adjusted Loss; Revenue Drops	Jan. 05
Top MIdday Decliners	Jan. 05
AngioDynamics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2023	Jan. 05
David D. Helsel to Leave AngioDynamics, Inc. as Senior Vice President of Global Operations and R&D, Effective January 12, 2024	Jan. 05
AngioDynamics, Inc. Provides Earnings Guidance for the Fiscal Year 2024	Jan. 05
AngioDynamics Completes Patient Enrollment in Device Trial for Pulmonary Embolism Treatment	Dec. 07
AngioDynamics, Inc. Completes Patient Enrollment in Apex-Av Study Assessing Alphavac F1885 System in Treatment of Pulmonary Embolism	Dec. 07
AngioDynamics, Inc. Reaffirms Earning Guidance for Fiscal Year 2024	23-10-04

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages AngioDynamics, Inc.

Equities

ANGO

US03475V1017

Other languages

Filters